← Clover Health Investments overview

Clover Health Investments vs Elevance Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Clover Health Investments Corp (CLOV)

Q3 2026
▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

  • Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.

    This regulatory win is a major new force behind CLOV's outlook and price.

  • Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.

    The profit swing and guidance raise are the clearest new evidence of improving finances.

  • Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.

    These operating drivers explain why results beat expectations and support the stock.

July 2026
▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

  • Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.

    This regulatory win is a major new force behind CLOV's outlook and price.

  • Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.

    The profit swing and guidance raise are the clearest new evidence of improving finances.

  • Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.

    These operating drivers explain why results beat expectations and support the stock.

Latest
▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

  • Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.

    This regulatory win is a major new force behind CLOV's outlook and price.

  • Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.

    The profit swing and guidance raise are the clearest new evidence of improving finances.

  • Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.

    These operating drivers explain why results beat expectations and support the stock.

Elevance Health Inc (ELV)

Q3 2026
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

July 2026
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

Latest
▲2▼2

Elevance beats Q2 but Medicaid margin drag and CMS lawsuit weigh

  • Medicaid margin turns negative, exits planned Elevance's Medicaid business is losing money, with a full-year margin of about -1.75%. The company is exiting Washington D.C. and more markets over 12-18 months. This drags overall profit and makes the 2027 growth target uncertain, pushing the stock down.

    This is the core reason the stock fell after earnings and is the main new negative force.

  • Elevance sues CMS over $115M Medicare Advantage bonus Elevance is suing Medicare's agency for recalculating a rival's star ratings after the fact, costing Elevance $115 million in bonus payments. The lawsuit adds regulatory uncertainty and could delay or reduce future bonus money, weighing on the stock.

    This is a new legal and regulatory risk that directly affects a revenue source.

  • Q2 earnings beat and guidance raised Elevance reported Q2 adjusted earnings of $7.45 per share, about 20% above estimates, and raised full-year guidance to at least $27.00. Revenue also beat. This shows the core business is stronger than expected, which supports the stock price.

    This is the main positive new event that initially lifted the stock before the Medicaid concerns took over.

  • Strong cash flow and buybacks support shares Elevance generated $4.3 billion in operating cash flow last quarter, expects at least $5.5 billion this year, and is buying back stock and paying dividends. This steady return of cash can cushion the stock and signals confidence.

    This is a new capital-return update that provides a positive counterweight to the margin issues.

Q2 2026
▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

June 2026
▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

▲3▼1

Elevance pushes tech and housing to offset regulatory and cost risks

  • Health OS cuts prior authorization denials by 61% Elevance's Health OS platform reduced prior authorization denials by 61% and sped up reviews, with over 30 health systems participating. This lowers administrative costs and improves efficiency, which can boost profit margins and support the stock price.

    This is a new operational improvement that directly lowers costs and supports earnings growth.

  • Carelon drives future earnings growth Carelon now makes up 36.3% of Elevance's revenue and uses AI to cut hospital readmissions by 20%. The company raised its 2026 profit guidance to at least $26.75 per share, showing confidence in this growth engine.

    Carelon's growing contribution and raised guidance are key positive drivers for future earnings.

  • CNSide deal expands covered lives to 45.4 million Elevance signed a national agreement with CNSide Diagnostics to offer a tumor cell test to about 45.4 million covered lives. This expands its service offerings and could attract more members, supporting revenue growth.

    New partnership expands covered lives and service portfolio, a direct demand driver.

  • No Surprises Act arbitration awards far exceed in-network rates An Elevance study found arbitration awards for planned procedures are often 50 times higher than in-network rates, raising costs. This could lead to regulatory scrutiny or policy changes that hurt insurers' profits.

    This highlights a regulatory and cost risk that could negatively impact Elevance's margins.

© 2026 MarketDXWhy